Drug Profile
Eos 004
Alternative Names: Eos-004Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Eos Biosciences
- Class Antineoplastics; Recombinant proteins; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Solid-tumours in USA (IV, Injection)